Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorCARsgen Therapeutics Co., Ltd.
About this trial
A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.
Eligibility criteria
Qualifiers
Voluntarily signed consent;
Age of ≥ 18;
Willing and able to adhere to trial visit schedule and other protocol requirements
Received sufficient prior lines of therapy;
Disqualifiers
Any significant condition(s), laboratory abnormality or psychiatric illness that would impair the ability of the participant to receive or tolerate the planned treatment or in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
Pregnant or lactating women;
HIV, active hepatitis C virus (HCV), or active hepatitis B virus (HBV) infection;
Any uncontrolled active infection;
Trial design
Treatments tested in this trial
- CT071
Treatment groups
166 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov